Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer.
Alan Pollack,Gail Walker,Eric M. Horwitz,Robert Price,Steven J. Feigenberg,Andre Konski,Radka Stoyanova,Benjamin Movsas,Richard E. Greenberg,Robert G. Uzzo,Charlie Ma,Mark K. Buyyounouski +11 more
Reads0
Chats0
TLDR
The hypofractionation regimen did not result in a significant reduction in BCDF; however, it is delivered in 2.5 fewer weeks; men with compromised urinary function before treatment may not be ideal candidates for this approach.Abstract:
Purpose To determine if escalated radiation dose using hypofractionation significantly reduces biochemical and/or clinical disease failure (BCDF) in men treated primarily for prostate cancer. Patients and Methods Between June 2002 and May 2006, men with favorable- to high-risk prostate cancer were randomly allocated to receive 76 Gy in 38 fractions at 2.0 Gy per fraction (conventional fractionation intensity-modulated radiation therapy [CIMRT]) versus 70.2 Gy in 26 fractions at 2.7 Gy per fraction (hypofractionated IMRT [HIMRT]); the latter was estimated to be equivalent to 84.4 Gy in 2.0 Gy fractions. High-risk patients received long-term androgen deprivation therapy (ADT), and some intermediate-risk patients received short-term ADT. The primary end point was the cumulative incidence of BCDF. Secondarily, toxicity was assessed. Results There were 303 assessable patients with a median follow-up of 68.4 months. No significant differences were seen between the treatment arms in terms of the distribution of ...read more
Citations
More filters
Journal ArticleDOI
Clinical practice guidelines in oncology
William J. Gradishar,Benjamin O. Anderson,Ron Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Janice A. Lyons,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Amy Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Rashmi Kumar,Dorothy A. Shead +32 more
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Guidelines on Prostate Cancer
Axel Heidenreich,Joaquim Bellmunt,Michel Bolla,Steven Joniau,Vsevolod Matveev,N. Mottet,Thomas Wiegel,Filiberto Zattoni +7 more
TL;DR: The introduction of an effective blood test, prostate specific antigen (PSA), has made it possible to diagnose more and more men in an earlier stage where they can be offered potentially curative treatments, and this is the subject of the EAU guidelines on prostate cancer.
Journal ArticleDOI
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David P. Dearnaley,Isabel Syndikus,Helen Mossop,Vincent Khoo,Alison Birtle,D. Bloomfield,John Graham,Peter Kirkbride,John P Logue,Zafar Malik,Julian Money-Kyrle,Joe M. O'Sullivan,Miguel Panades,Chris Parker,Helen Patterson,Christopher D Scrase,John Staffurth,Andrew Stockdale,Jean Tremlett,M. Bidmead,Helen Mayles,O. Naismith,C. South,Annie Gao,Clare Cruickshank,Shama Hassan,Julia Pugh,Clare Griffin,Emma Hall +28 more
TL;DR: Hypofractionated radiotherapy using 60 Gy in 20 fractions is non-inferior to conventional fractionation using 74 Gy in 37 fractions and is recommended as a new standard of care for external-beam radiotherapy of localised prostate cancer after 5 years follow-up.
Journal ArticleDOI
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
W. James Morris,W. James Morris,Scott Tyldesley,Sree Rodda,Ross Halperin,Howard Pai,Michael McKenzie,Michael McKenzie,G. Duncan,Gerard Morton,Jeremy Hamm,Nevin Murray +11 more
TL;DR: Compared with 78 Gy EBRT, men randomized to the LDR-PB boost were twice as likely to be free of biochemical failure at a median follow-up of 6.5 years and no significant overall survival difference was observed between the treatment arms.
Journal ArticleDOI
Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer
Charles Catton,Himu Lukka,Chu-Shu Gu,Jarad Martin,Stéphane Supiot,Peter Chung,Glenn Bauman,Jean-Paul Bahary,Shahida Ahmed,Patrick Cheung,Keen Hun Tai,Jackson S.Y. Wu,Matthew Parliament,Theodoros Tsakiridis,Tom Corbett,Colin Tang,Ian S. Dayes,Padraig Warde,Tim Craig,Jim A. Julian,Mark Levine +20 more
TL;DR: The hypofractionated RT regimen used in this trial was not inferior to conventional RT and was not associated with increased late toxicity, and should be considered for intermediate-risk prostate cancer.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Jason P. Fine,Robert Gray +1 more
TL;DR: This article proposes methods for combining estimates of the cause-specific hazard functions under the proportional hazards formulation, but these methods do not allow the analyst to directly assess the effect of a covariate on the marginal probability function.
Journal Article
Evaluation of survival data and two new rank order statistics arising in its consideration.
Journal ArticleDOI
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
TL;DR: In this paper, a class of tests developed for comparing the cumulative incidence of a particular type of failure among different groups is presented. The tests are based on comparing weighted averages of the hazards of the subdistribution for the failure type of interest.
Journal ArticleDOI
The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.
Michael J. Barry,Floyd J. Fowler,Michael P. O'Leary,Reginald C. Bruskewitz,Holtgrewe Hl,Winston K. Mebust,Abraham T.K. Cockett +6 more
TL;DR: The AUA symptom index for benign prostatic hyperplasia was developed and validated by a multidisciplinary measurement committee of the American Urological Association and is clinically sensible, reliable, valid and responsive.
Related Papers (5)
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David P. Dearnaley,Isabel Syndikus,Helen Mossop,Vincent Khoo,Alison Birtle,D. Bloomfield,John Graham,Peter Kirkbride,John P Logue,Zafar Malik,Julian Money-Kyrle,Joe M. O'Sullivan,Miguel Panades,Chris Parker,Helen Patterson,Christopher D Scrase,John Staffurth,Andrew Stockdale,Jean Tremlett,M. Bidmead,Helen Mayles,O. Naismith,C. South,Annie Gao,Clare Cruickshank,Shama Hassan,Julia Pugh,Clare Griffin,Emma Hall +28 more
Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer
W. Robert Lee,James J. Dignam,Mahul B. Amin,Deborah Watkins Bruner,Daniel A. Low,Gregory P. Swanson,Amit Shah,David D'Souza,Jeff M. Michalski,Ian S. Dayes,Samantha A. Seaward,William A. Hall,Paul L. Nguyen,Thomas M. Pisansky,Sergio Faria,Yuhchyau Chen,Bridget F. Koontz,Rebecca Paulus,Howard M. Sandler +18 more
Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer
Charles Catton,Himu Lukka,Chu-Shu Gu,Jarad Martin,Stéphane Supiot,Peter Chung,Glenn Bauman,Jean-Paul Bahary,Shahida Ahmed,Patrick Cheung,Keen Hun Tai,Jackson S.Y. Wu,Matthew Parliament,Theodoros Tsakiridis,Tom Corbett,Colin Tang,Ian S. Dayes,Padraig Warde,Tim Craig,Jim A. Julian,Mark Levine +20 more